Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View

GH
Guardant Health, Inc. Common Stock
stock NASDAQ

At Close
Oct 17, 2025 3:59:57 PM EDT
65.43USD-2.980%(-2.01)1,611,875
65.42Bid   65.43Ask   0.01Spread
Pre-market
Oct 17, 2025 9:11:30 AM EDT
66.60USD-1.246%(-0.84)300
After-hours
Oct 17, 2025 4:45:30 PM EDT
65.74USD+0.474%(+0.31)3,400
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 19, 2022
08:05AM EST  Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium   Business Wire
Jan 18, 2022
08:15AM EST  Guardant Health Enrolls First Patient In SHIELD LUNG Study To Evaluate Accuracy Of Its Blood Test To Detect Lung Cancer In High-Risk Adults   Benzinga
Jan 7, 2022
05:15PM EST  Guardant Health and Foundation Medicine Reach Settlement in Digital Sequencing Technology Litigation   Business Wire
Dec 29, 2021
08:05AM EST  Guardant Health to Participate Virtually in the 40th Annual J.P. Morgan Healthcare Conference   Business Wire
Dec 17, 2021
08:09AM EST  Guardant Health Reports Reached Target Enrollment Of 12.75K Patients In ECLIPSE Study For Its LUNAR-2 Blood Test To Detect Colorectal Cancer   Benzinga
08:05AM EST  Guardant Health Reaches Target Enrollment of 12,750 Patients in ECLIPSE Pivotal Study for its LUNAR(tm)-2 Blood Test to Detect Colorectal Cancer   Business Wire
Dec 6, 2021
08:14AM EST  Guardant Health Presents Data Demonstrating Utility Of Comprehensive Genetic Profiling With Guardant360 Liquid Biopsy Test To Guide Treatment For Advanced Breast Cancer Patients At 2021 San Antonio Breast Cancer Symposium   Benzinga
08:05AM EST  Guardant Health Presents Data Demonstrating Utility of Comprehensive Genetic Profiling with Guardant360(r) Liquid Biopsy Test to Guide Treatment for Advanced Breast Cancer Patients at 2021 San Antonio Breast Cancer Symposium   Business Wire
Nov 24, 2021
05:22AM EST  Guardant Health Co-CEO AmirAli Talasaz Reported Purchase of 104,500 Shares @ Avg Price of $96.12/Share in Form 4 Filing on Tuesday   Benzinga
Nov 22, 2021
01:45PM EST  Detecting Early Cancer Screening Stocks At An Early Stage Is Critical   Benzinga
Nov 12, 2021
07:47AM EST  The Daily Biotech Pulse: J&J To Spin-off Consumer Health Business, AstraZeneca Earnings, Embattled Emergent To Buy Back Shares   Benzinga
Nov 11, 2021
04:16PM EST  Guardant Health Highlights Publication Of Study In Nature Medicine On Guardant360 Liquid Biopsy Test   Benzinga
04:05PM EST  Study Shows Guardant360(r) Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer   Business Wire
Nov 8, 2021
04:06PM EST  Guardant Health to Participate in the 2021 Stifel Healthcare Conference   Business Wire
Nov 5, 2021
09:38AM EDT  SVB Leerink Maintains Outperform on Guardant Health, Lowers Price Target to $170   Benzinga
09:31AM EDT  Guardant Health: Q3 Earnings Insights   Benzinga
09:29AM EDT  Guardant Health Sees FY21 Sales $360M-$370M Vs. $366.68M Est.   Benzinga
09:29AM EDT  Guardant Health Q3 EPS $(0.70) Beats $(0.96) Estimate, Sales $94.78M Beat $92.64M Estimate   Benzinga
Nov 4, 2021
04:05PM EDT  Guardant Health Reports Third Quarter 2021 Financial Results   Business Wire
08:19AM EDT  The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO   Benzinga
05:00AM EDT  Earnings Scheduled For November 4, 2021   Benzinga
Nov 3, 2021
08:05PM EDT  Guardant Health and The Royal Marsden NHS Foundation Trust Announce Partnership to Establish First Guardant Health Liquid Biopsy Testing Service Based in the United Kingdom   Business Wire
Oct 31, 2021
02:24PM EDT  The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline   Benzinga
Oct 25, 2021
08:05AM EDT  Data Presented at ACG Shows Guardant Health's Blood-Based Test Accurately Detects Early-Stage Colorectal Cancer   Business Wire
Oct 20, 2021
04:30PM EDT  Guardant Health Appoints Myrtle Potter to Its Board of Directors   Business Wire
Oct 8, 2021
08:05AM EDT  Guardant Health to Report Third Quarter Financial Results on November 4, 2021   Business Wire
Oct 5, 2021
08:09AM EDT  Guardant Health Reports Initiation Of ORACLE Study To Evaluate Performance Of Co.'s Reveal Blood Test To Predict Recurrence Across Early-Stage Cancers   Benzinga
08:05AM EDT  Guardant Health Initiates ORACLE Study to Evaluate Performance of Guardant Reveal(tm) Blood Test to Predict Recurrence Across Early-Stage Cancers   Business Wire
Oct 4, 2021
12:08PM EDT  Guardant Health Will Not Go With NeoGenomics Deal: Bloomberg   Benzinga
05:02AM EDT  Bloomberg Reported Sunday Guardant Health Decided Against Buying NeoGenomics   Benzinga
Sep 15, 2021
04:00AM EDT  Guardant Health Showcases Data at ESMO 2021 Demonstrating Utility of Guardant360(r) Liquid Biopsy to Obtain Comprehensive Molecular Information to Guide Targeted Therapy Options for Late-Stage Cancers   Business Wire
Sep 7, 2021
08:23AM EDT  New Data at IASLC 2021 World Conference On Lung Cancer Demonstrates Advantages Of Using the Guardant360 Liquid Biopsy Blood Test For Comprehensive Genomic Profiling In Advanced Lung Cancer   Benzinga
08:05AM EDT  New Data at IASLC 2021 World Conference on Lung Cancer   GlobeNewswire Inc
Sep 2, 2021
04:05PM EDT  Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the company will be participating virtually in the upcoming Morgan Stanley Global Healthcare Conference.   GlobeNewswire Inc
Sep 1, 2021
11:13AM EDT  Return on Capital Employed Insights for Guardant Health   Benzinga
Aug 6, 2021
04:15PM EDT  Guardant Health to Participate in the UBS Genomics 2.0 and MedTech Innovations Summit   Business Wire
09:35AM EDT  Precision Oncology Sales Boost Guardant Health Q2 Topline, Backs FY21 Outlook, Management Updates   Benzinga
07:42AM EDT  The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO   Benzinga
Aug 5, 2021
06:01PM EDT  Guardant Health Reports CEO Helmy Eltoukhy, President AmirAli Talasaz To Serve as Co CEOs; Eltoukhy To Assume Role Of Chair   Benzinga
05:15PM EDT  Guardant Health Sees FY21 Sales $360M-$370M Vs. $367.97M Est.   Benzinga
05:15PM EDT  Guardant Health Q2 EPS $(0.96) Misses $(0.87) Estimate, Sales $92.10M Beat $84.61M Estimate   Benzinga
04:06PM EDT  Guardant Health Announces New Leadership Structure Aligned with Strategic Growth Objectives and Expands Board of Directors   Business Wire
04:03PM EDT  Guardant Health Reports Second Quarter 2021 Financial Results   Business Wire
08:08AM EDT  The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO   Benzinga
04:08AM EDT  Earnings Scheduled For August 5, 2021   Benzinga
Aug 3, 2021
12:12PM EDT  TwinStrand Biosciences Reports Filed Patent Infringement Suit Against Guardant Health   Benzinga
Jul 20, 2021
08:10AM EDT  Fight Colorectal Cancer and Guardant Health Join Forces to Recognize Excellence in Overcoming Challenges to Colorectal Cancer Screening During Pandemic   Business Wire
Jul 19, 2021
06:39PM EDT  AI Startup Lunit Secures Investment from Guardant Health in a Strategic Funding   PR Newswire
09:33AM EDT  Lunit Reports $26M Strategic Investment From Guardant Health, No Terms Disclosed   Benzinga
Jul 13, 2021
08:05AM EDT  Guardant Health to Report Second Quarter Financial Results on August 5, 2021   Business Wire
Jun 30, 2021
07:29AM EDT  The Daily Biotech Pulse: COVID Disappointments For Altimmune And Angion, Brickell Jumps On Hyperhidrosis Study Updates, 2 IPOs   Benzinga
Jun 22, 2021
08:13AM EDT  Guardant Health Adds New Products To Portfolio To Help Improve Management Of Patients With Metastatic Cancers   RTTNews
08:10AM EDT  Guardant Health Highlights Addition Of Guardant360 Response Blood Test And Guardant360 TissueNext Tissue Biopsy Test To Portfolio   Benzinga
08:05AM EDT  Guardant Health Expands Guardant360(r) Portfolio With New Tests for Treatment Response Monitoring and Complete Genomic Profiling   Business Wire
Jun 21, 2021
09:38AM EDT  Guardant Health Insights: Return On Capital Employed   Benzinga
07:06AM EDT  Wells Fargo Maintains Overweight on Guardant Health, Raises Price Target to $160   Benzinga
Jun 18, 2021
08:23PM EDT  CORRECTING and REPLACING Study Shows Guardant Reveal(tm) Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity   Business Wire
07:57PM EDT  CORRECTING and REPLACING Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers   Business Wire
Jun 15, 2021
10:24AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2021   Benzinga
08:17AM EDT  Raymond James Initiates Coverage On Guardant Health with Market Perform Rating   Benzinga
Jun 8, 2021
08:10AM EDT  Guardant Health Appoints Chris Freeman As Chief Commercial Officer For Its Oncology Business   RTTNews
08:05AM EDT  Guardant Health Announces Appointment of Chris Freeman as Chief Commercial Officer   Business Wire
Jun 4, 2021
10:50AM EDT  Guardant Health: Return On Capital Employed Insights   Benzinga
09:10AM EDT  Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Blood Test Highly Accurate in Detecting Colorectal Cancer in Patients With Early-Stage Cancer   Business Wire
Jun 3, 2021
10:09AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For June 3, 2021   Benzinga
06:38AM EDT  Goldman Sachs Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $160   Benzinga
May 28, 2021
02:29PM EDT  Amgen's First KRAS-Targeted Therapy, Lumakras Scores FDA Approval For Lung Cancer   Benzinga
01:15PM EDT  Guardant Health Reports FDA Approved Guardant 360 CDx Test For KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer   Benzinga
01:15PM EDT  Guardant360(r) CDx Receives FDA Approval as First and Only Liquid Biopsy Companion Diagnostic for Amgen's LUMAKRAS(tm) (sotorasib) KRASG12C Inhibitor for Use in Advanced Non-Small Cell Lung Cancer   Business Wire
02:00AM EDT  Guardant Health Inc. (GH) said that it filed a lawsuit against Natera Inc. for false advertising, unfair competition, and unlawful trade practices, relating to misleading statements Natera has made about its own products and the performance of Guardant Health's new oncology test, Guardant Reveal.   RTTNews
01:54AM EDT  Guardant Health Says Files Lawsuit Against Natera For Misleading Oncologists   RTTNews
01:52AM EDT  Guardant Health Files Lawsuit Against Natera for Misleading Oncologists   Business Wire
May 25, 2021
10:50AM EDT  Where Guardant Health Stands With Analysts   Benzinga
10:02AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021   Benzinga
07:20AM EDT  Wells Fargo Initiates Coverage On Guardant Health with Overweight Rating, Announces Price Target of $145   Benzinga
May 21, 2021
03:15PM EDT  Guardant Health Reports FDA Approval Of Guardant360 CDx Liquid Biopsy Test As Companion Diagnostic For Janssen's RYBREVANT   Benzinga
03:14PM EDT  Guardant360(r) CDx Receives FDA Approval as Companion Diagnostic for Janssen's RYBREVANT(tm) (amivantamab-vmjw) for Use in Patients with Advanced Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations   Business Wire
May 20, 2021
08:05AM EDT  Guardant Health to Participate in Upcoming June Investor Conferences   Business Wire
May 19, 2021
05:57PM EDT  Guardant Health Presents Data at 2021 ASCO Annual Meeting Showing Utility of Liquid Biopsy in Early- and Late-Stage Cancers   Benzinga
May 7, 2021
11:11AM EDT  What 7 Analyst Ratings Have To Say About Guardant Health   Benzinga
10:00AM EDT  BTIG Maintains Buy on Guardant Health, Raises Price Target to $160   Benzinga
08:16AM EDT  Morgan Stanley Maintains Overweight on Guardant Health, Lowers Price Target to $160   Benzinga
May 6, 2021
04:55PM EDT  Guardant Health Sees FY21 Sales $360M-$370M Vs $367.76M Estimates   Benzinga
04:53PM EDT  Guardant Health Q1 EPS $(0.49) Beats $(0.89) Estimate, Sales $78.67M Beat $73.75M Estimate   Benzinga
04:06PM EDT  Guardant Health Reports First Quarter 2021 Financial Results   Business Wire
07:49AM EDT  The Daily Biotech Pulse: Merck's Keytruda Snags Another FDA Approval, Moderna Slips On Revenue Miss, Chemocentryx Adcom   Benzinga
04:17AM EDT  Earnings Scheduled For May 6, 2021   Benzinga
May 3, 2021
08:12AM EDT  Guardant Health Appoints Craig Eagle As Chief Medical Officer   RTTNews
08:05AM EDT  Guardant Health Appoints Craig Eagle, MD as Chief Medical Officer   Business Wire
Apr 30, 2021
08:16AM EDT  Guardant Highlights Publication Of Guardant Reveal Study   Benzinga
08:05AM EDT  Study Shows Guardant Reveal(tm) Blood-Only Liquid Biopsy Test Predicts Risk for Colorectal Cancer Recurrence with Industry-Leading Sensitivity   Business Wire
Apr 29, 2021
08:05AM EDT  Guardant Health to Participate in the BofA Securities 2021 Healthcare Conference   Business Wire
Apr 27, 2021
08:24AM EDT  Guardant Health Announces Collaboration With Daiichi Sankyo to Develop Guardant360 CDx as a Companion Diagnostic for Enhertu in Advanced Metastatic Non-Small Cell Lung Cancer   Benzinga
08:12AM EDT  Guardant Health Announces Collaboration With Daiichi Sankyo To Develop Guardant360 CDx   RTTNews
08:05AM EDT  Guardant Health Announces Collaboration With Daiichi Sankyo to Develop Guardant360(r) CDx as a Companion Diagnostic for Enhertu(r) in Advanced Metastatic Non-Small Cell Lung Cancer   Business Wire
Apr 12, 2021
04:05PM EDT  Guardant Health to Report First Quarter Financial Results on May 6, 2021   Business Wire
Apr 10, 2021
08:35AM EDT  Data at AACR Demonstrate Growing Clinical Utility of Guardant Health Liquid Biopsies in the Treatment and Management of Advanced Cancers   Business Wire
Apr 1, 2021
08:07AM EDT  Guardant Health Receives New York State CLEP Approval For Guardant Reveal Blood Test To Detect And Monitor Residual Disease In Patients With Early-Stage Cancer   Benzinga
Mar 30, 2021
08:13AM EDT  Guardant Health Receives ADLT Status From CMS For FDA-Approved Guardant360 CDx Test   RTTNews
08:06AM EDT  Guardant Health Reports Receives Advanced Diagnostic Lab Test Status For Its Guardant360 CDx Test   Benzinga
08:05AM EDT  Guardant Health Receives ADLT Status from CMS for FDA-Approved Guardant360(r) CDx Test   Business Wire
Mar 26, 2021
08:06AM EDT  Guardant Health Highlights Study It Says Shows Guardant360 Liquid Biopsy Predicts Response To Pembrolizumab-Based Immunotherapy In Patients With Metastatic Non-Small Cell Lung Cancer   Benzinga
08:05AM EDT  Study Shows Guardant360 Liquid Biopsy Predicts Response to Pembrolizumab-Based Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer   Business Wire
Mar 24, 2021
08:05AM EDT  Guardant Health Joins Forces With Patient Advocacy Groups to Raise Awareness of Importance of Complete Biomarker Testing for Patients With Advanced Colorectal Cancer   Business Wire
Mar 2, 2021
08:11AM EST  Guardant Health Reports Guardant360 CDx For Tumor Mutation Profiling Wins CE Mark   Benzinga
08:05AM EST  Guardant360(r) CDx Liquid Biopsy CE-Marked for Comprehensive Tumor Mutation Profiling Across All Solid Cancers   Business Wire
Feb 26, 2021
08:48AM EST  Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $175   Benzinga
Feb 25, 2021
11:43AM EST  Cowen & Co. Maintains Outperform on Guardant Health, Raises Price Target to $190   Benzinga
11:13AM EST  Citigroup Maintains Buy on Guardant Health, Raises Price Target to $190   Benzinga
08:08AM EST  The Daily Biotech Pulse: Merck Goes Shopping, Decision Day For Sarepta, Pfizer, Moderna Unveil Vaccine Strategies For Coronavirus Variants   Benzinga
Feb 24, 2021
04:31PM EST  Guardant Health Sees FY21 Sales $360M-$370M Vs $377.07M Estimates   Benzinga
04:30PM EST  Guardant Health Q4 EPS $(0.94) Misses $(0.57) Estimate, Sales $78.32M Beat $76.73M Estimate   Benzinga
04:29PM EST  Guardant Health: Q4 Earnings Insights   Benzinga
04:06PM EST  Guardant Health Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Revenue Outlook for Full Year 2021   Business Wire
07:30AM EST  The Daily Biotech Pulse: Bausch Calls Truce With Icahn, Pfizer's Brain Inflammation Vaccine Gets Priority Review, BriaCell IPO   Benzinga
03:35AM EST  Earnings Scheduled For February 24, 2021   Benzinga
Feb 23, 2021
10:24AM EST  Guardant Health Earnings Preview   Benzinga
Feb 17, 2021
04:03PM EST  Guardant Health to Participate in Upcoming Investor Conferences   Business Wire
Feb 16, 2021
08:11AM EST  Guardant Health Launches Guardant Reveal Liquid Biopsy Test For Residual Disease And Recurrence Monitoring In Patients With Early-Stage Colorectal Cancer   Benzinga
Feb 4, 2021
04:03PM EST  Guardant Health to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021   Business Wire
Jan 27, 2021
08:08AM EST  Guardant Health: Study Shows Guardant360 Liquid Biopsy Outperforms Tissue Biopsy For Genomic Profiling In Advanced NSCLC   RTTNews
08:07AM EST  Guardant Health Highlights Publication Of Study Showing Guardant360 'Outperforms Tissue Biopsy for Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer with Similar Outcomes'   Benzinga
08:05AM EST  Head-to-Head Study Shows Guardant360 Liquid Biopsy Outperforms Tissue Biopsy for Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer with Similar Outcomes   Business Wire
Jan 21, 2021
08:05AM EST  The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping   Benzinga
Jan 20, 2021
04:44AM EST  SVB Leerink Maintains Outperform on Guardant Health, Raises Price Target to $190   Benzinga
Jan 18, 2021
03:15AM EST  Guardant Health And Vall D'Hebron Institute Of Oncology Announce Partnership   RTTNews
03:01AM EST  Guardant Health and Vall d'Hebron Institute of Oncology Announce Partnership to Establish First Guardant-Based Liquid Biopsy Testing Service in Europe   Business Wire
Jan 14, 2021
08:26AM EST  Guardant Health To Present Data At ASCO Gastrointestinal Cancers Symposium Showing Value Of Liquid Biopsy To Advance Precision Oncology In Early To Late-Stage Colorectal Cancer   Benzinga
07:57AM EST  The Daily Biotech Pulse: Alexion Pauses COVID-19 Study, NantKwest Readout, Organogenesis Jumps On Guidance, Trial Updates   Benzinga
Jan 13, 2021
07:25AM EST  The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations   Benzinga
Jan 12, 2021
08:16AM EST  The Daily Biotech Pulse: GSK, Vir To Start COVID-19 Antibody Study, Novartis In-Licenses BeiGene's Cancer Drug, Earnings Preannouncements Continue   Benzinga
Jan 11, 2021
10:06AM EST  Benzinga's Top Upgrades, Downgrades For January 11, 2021   Benzinga
06:05AM EST  Stifel Initiates Coverage On Guardant Health with Buy Rating, Announces Price Target of $175   Benzinga
Dec 30, 2020
04:03PM EST  Guardant Health to Participate in the 39th Annual J.P. Morgan Healthcare Conference   Business Wire
Dec 23, 2020
08:31AM EST  The Daily Biotech Pulse: Supernus Issues Positive ADHD Readout, Sorrento Files For Emergency Use Authorization For Rapid COVID-19 Test, Inhibikase To Make Wall Street Debut   Benzinga
Dec 22, 2020
07:45AM EST  The Daily Biotech Pulse: Ziopharm To Start Blood Cancer Study, Chemocentryx & Soligenix Slump On Adverse Clinical Trial Outcomes   Benzinga
Dec 11, 2020
05:00PM EST  Guardant Health Names Michael Bell As CFO   Benzinga
05:00PM EST  Guardant Health Names Michael Bell as New Chief Financial Officer   Business Wire
06:17AM EST  SVB Leerink Maintains Outperform on Guardant Health, Raises Price Target to $150   Benzinga
Dec 10, 2020
07:42AM EST  The Daily Biotech Pulse: Key Vaccine Adcom Review For Pfizer-BioNTech, Puma, Immutep, G1 Rally On Breast Cancer Conference Presentations   Benzinga
Dec 8, 2020
08:04AM EST  The Daily Biotech Pulse: ASH Presentations, Axsome's Positive Midstage Readout, Follow-On Offerings   Benzinga
Dec 7, 2020
08:05AM EST  Guardant Health Presents Data at San Antonio Breast Cancer Symposium Demonstrating Utility of GuardantINFORM(tm) Real-World Platform in Metastatic Breast Cancer   Business Wire
Dec 2, 2020
07:35AM EST  The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod   Benzinga
Nov 16, 2020
11:33PM EST  Guardant Health Prices $1 Bln Convertible Senior Notes Offering Due 2027 In A Private Offering   RTTNews
11:22PM EST  Guardant Health, Inc. Prices $1 Billion Convertible Senior Notes Offering   Business Wire
06:58AM EST  Guardant Health To Offer $1 Bln Convertible Notes Due 2027 In A Private Offering To Qualified Institutional Buyers   RTTNews
06:47AM EST  Guardant Health, Inc. Announces Proposed Convertible Senior Notes Offering   Business Wire
Nov 13, 2020
07:40AM EST  The Daily Biotech Pulse: Urovant In M&A Deal, Sanofi's Binary Event, Conference Presentations   Benzinga
Nov 9, 2020
08:27AM EST  Morgan Stanley Maintains Overweight on Guardant Health, Raises Price Target to $130   Benzinga
Nov 6, 2020
07:47AM EST  The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold   Benzinga
Nov 5, 2020
04:20PM EST  Guardant Health Q3 EPS $(0.78) Misses $(0.39) Estimate, Sales $74.60M Beat $65.84M Estimate   Benzinga
04:03PM EST  Guardant Health Reports Third Quarter 2020 Financial Results   Business Wire
07:54AM EST  The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping   Benzinga
04:34AM EST  Earnings Scheduled For November 5, 2020   Benzinga
Nov 1, 2020
09:40AM EST  The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings   Benzinga
Oct 16, 2020
04:05PM EDT  Guardant Health Announces Webcast of Third Quarter Financial Results on November 5, 2020   Business Wire
Oct 15, 2020
04:05PM EDT  Guardant Health Announces Closing of Public Offering of Common Stock, Including Option to Purchase Additional Shares by Selling Stockholder   Business Wire
Oct 11, 2020
11:08AM EDT  Cramer Shares His Thoughts On NCino, AT&T And More   Benzinga
Oct 7, 2020
10:22AM EDT  Return On Capital Employed Overview: Guardant Health   Benzinga
09:14AM EDT  Guardant Health Announces Pricing Of 7 Mln Shares By Selling Stockholder At $102/shr   RTTNews
09:07AM EDT  Guardant Health Prices 7M Share Offering At $102/Share   Benzinga
09:06AM EDT  Guardant Health Announces Pricing of Public Offering of Common Stock by Selling Stockholder   Business Wire
Oct 6, 2020
04:55PM EDT  Guardant Health Announces A Proposed Common Stock Offering Of 7M Offering By Selling Stockholder Shares   Benzinga
04:54PM EDT  Guardant Health Announces Proposed Public Offering of Common Stock by Selling Stockholder   Business Wire
Oct 5, 2020
04:05PM EDT  Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy   Business Wire
Sep 9, 2020
09:45AM EDT  Benzinga's Top Upgrades, Downgrades For September 9, 2020   Benzinga
06:21AM EDT  Morgan Stanley Initiates Coverage On Guardant Health with Overweight Rating, Announces Price Target of $110   Benzinga
Sep 1, 2020
04:03PM EDT  Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the upcoming Morgan Stanley Virtual Healthcare Conference.   GlobeNewswire Inc
Aug 24, 2020
03:44PM EDT  Guardant Health shares are trading higher after the company received Emergency Use Authorization from the FDA for its Guardant-19 next generation sequencing-based Covid-19 test.   Benzinga
08:19AM EDT  Guardant Health Receives FDA Emergency Use Authorization for its Guardant-19 Next Generation Sequencing-Based COVID-19 Test   Benzinga
08:05AM EDT  Guardant Health, Inc.(Nasdaq: GH) announces that the U.S. Food and Drug Administration (FDA) has granted the Guardant-19 test emergency use authorization (EUA) for use in the detection of the novel coronavirus, SARS-CoV-2. The test is being offered to Guardant Health employees and select partner organizations through the companys CLIA-certified clinical laboratory.   GlobeNewswire Inc
Aug 10, 2020
08:05AM EDT  Guardant Health, Inc. (Nasdaq: GH) today announced the company will be participating in the following investor virtual conferences.   GlobeNewswire Inc
Aug 7, 2020
02:28PM EDT  Guardian Health Guardant360 CDx First FDA-Approved Liquid Biopsy For Comprehensive Tumor Mutation Profiling Across All Solid Cancers   Benzinga
02:26PM EDT  Guardant Health Guardant360 CDx First FDA-Approved   GlobeNewswire Inc
Aug 6, 2020
04:40PM EDT  Guardant Health Q2 EPS $(0.57) Misses $(0.38) Estimate, Sales $66.30M Beat $59.17M Estimate   Benzinga
07:57AM EDT  The Daily Biotech Pulse: FDA Nod For GlaxoSmithKline, Bristol-Myers Squibb Earnings, Acutus Medical IPO   Benzinga
Jul 30, 2020
05:07PM EDT  Guardant Health Reports Collaboration With Radius Health To Develop Liquid Biopsy Companion Diagnostic For Elacestrant   Benzinga
Jul 21, 2020
08:05AM EDT  Guardant Health, Inc. (Nasdaq: GH) today announced it will report financial results for the second quarter 2020 after market close on Thursday, August 6, 2020. Company management will be webcasting a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.   GlobeNewswire Inc


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC